GPHL broke ground on the construction of its R&D and marketing headquarters located at Guangzhou’s International Biotech Island (GIBI) on the morning of March 1st, 2019. The corporation’s Chairman Li Chuyuan attended the groundbreaking ceremony and put forward three demands for the team after visiting the construction site.

Li said that all should be undertaken in accordance with law, all should put safety first and guarantee quality, so as to ensure the project’s success.

With investment totalling around 1 billion RMB, the project, covering an area of 31,000 square meters, includes an R&D center, an incubation and innovation base, a laboratory, and a detection center.

It is one of the 35 major projects, with a total investment amount of 102.3 billion yuan ($15.2 billion), launched by Huangpu District and Guangzhou Development Zone on GIBI, including 15 industrial development projects, seven science and technology business complex projects, seven urban renewal projects, and six municipal supporting facilities projects.

On March 1st, 35 projects, with a total investment amount of 102.3 billion yuan ($15.2 billion), break ground. [Photo/www.hp.gov.cn]

The projects focus on strategic emerging industries such as biomedicine, new energy, new materials and advanced manufacturing industries, as well as innovative carriers such as science and technology incubators and comprehensive science and technology innovation industrial parks, and there are also a large number of urban renewal projects, including renovation of old villages such as Shabu Village and Hongwei Village, according to China Daily. It is estimated that the annual output value will reach 211.8 billion yuan after all projects are completed.

GPHL’s Chairman Li Chuyuan (R5) poses for a photo with companions at the construction site.

Covering an area of 1.83 square kilometers, GIBI is located in the geographic center of Guangzhou. Its primary aim is to introduce domestic and overseas high-end biotechnology enterprise headquarters and R&D centers, biotechnology research and development institutions, biological service enterprises and organizations which provide professional supporting services, and relevant financial investment organizations which provide such services as investment and financing and IPO listing for the development of the bio-pharmaceutical industry.

Reported by Monica Liu

Edited by Simon Haywood